We’re providing updates on the COVID-19 situation for the UK drug discovery community. Our aim is to help the community during this challenging time and also highlight important work and resources.
INNO4COV-19 Open Call
INNO4COV-19 Open Call aims to provide financial support to companies with the goal of accelerating the development and commercialization of innovative solutions that tackle COVID-19 and that have already been validated in lab environments (TRL6 or higher).
Open call for research and innovation ideas to address COVID-19
Proposals are invited for short term projects addressing and mitigating the health, social, economic and environmental impacts of the COVID-19 outbreak.
UKRI will support excellent proposals of up to 18 months duration which meet at least one of the following:
- New research or innovation with a clear impact pathway that has the potential (within the period of the award) to deliver a significant contribution to the understanding of, and response to, the COVID-19 pandemic and its impacts.
- Supports the manufacture and/or wide scale adoption of an intervention with significant potential
- Gathers critical data and resources quickly for future research use
Proposals will be accepted from anyone who is normally eligible to apply for UKRI funding. Proposals should be sent through this route for any research or innovation relevant to the above regardless of funding Council or whether relevant to multiple Councils.
Requests to switch existing UKRI award funding to address Covid-19 research priorities
UKRI has put processes in place to allow researchers to repurpose existing UKRI award funding to address COVID-19 research priorities.
Investing in the Future: Structural R&D Projects for Competitivity – COVID19
Administered by Bpifrance, France’s public investment bank, this Investing in the Future call, Structural Research and Development Projects for Competitivity – COVID-19, will provide funding (a combination of grants and repayable advances) to collaborative structural research and development projects to develop preventative or curative therapeutic solutions to coronavirus/COVID-19. Direct economic and technological effects in the form of new products, services or technology are expected. In return for the aid provided, the State may be granted preferential access rights to to the results of the project. This may take the form, for example, of access to the final products developed. As part of the fight against the COVID-19 pandemic, this will be the preferred method of return for the State.
Government support for research related to COVID-19
COVID-19 Urgent Public Health Research is being prioritised to gather the necessary clinical and epidemiological evidence that will inform national policy and enable new diagnostic tests, treatments and vaccines to be developed and tested for COVID-19.
Government support is available to prioritise, coordinate and deliver these studies, regardless of sponsorship and funding source. This support includes expedited identification of sites to ensure appropriate geographical distribution of Urgent Public Health Research to maximise recruitment and minimise over-commitment of resource.
Organisation: European Open Science Cloud (EOSC) Secretariat
Fast Track Process for COVID-19 Co-Creation Request
European Open Science Cloud EOSC is an ideal tool to respond to public emergencies such as the COVID-19 virus by:
- Opening up scientific data on the virus
- Sharing live on-the-ground data on the spread of the virus, as well as software, standards and processes for monitoring COVID-19 treatment and development
- Accessing and combining this data not only to eradicate the virus but learn how to deal with similar viruses and future outbreaks
- Assessing the validity of epidemic information in relation to the virus by ensuring that its sources can be traced and verified.
The EOSC Secretariat responds to this clear need for stakeholder engagement by introducing funding opportunities that will be fast-tracked at this challenging time.
Activities and actions that deploy open science methods and resources and make use of the EOSC communities in order to address COVID-19 related issues. These could be:
- Opening up virus related research and data
- Sharing of infrastructures and services
- Developing open design equipment for fighting COVID-19
- Sharing sampling test methodologies and data
- Developing open methodologies, services, software and infrastructures for sharing data, practices and knowledge in relation to the development and treatment of COVID-19
- Developing open science methodologies for monitoring the spread of COVID-19
- Developing open-science / evidence-based methodologies for the development of epidemic combating policies
- Accessing and combining open data not only to eradicate the virus but learn how to deal with similar viruses and future outbreaks
- Assessing the validity of epidemic information in relation to the virus by ensuring that its sources can be traced and verified
- Other open science activities/ actions related to the fighting of epidemics and pandemics
Organisation: Emergent Ventures
Fast Funding for COVID-19 Science
If you are a scientist currently working on a COVID-19 related project and in need of funding, you are invited to apply for a Fast Grant. Fast Grants are $10k to $500k and decisions are made within 14 days. If the grant is approved, you’ll receive payment as quickly as your university can receive it.
Organisation: Therapeutics Accelerator
COVID-19 Therapeutics Accelerator (CTA)
The COVID-19 Therapeutics Accelerator (CTA) is a philanthropic initiative designed to coordinate R&D efforts, remove barriers to drug development and scale up treatments to address the pandemic.